

ACKNOWLEDGMENTS AND DISCLOSURES

The research reported in this article was supported by grants from Johnson & Johnson awarded to University College London (HVC) and King's College London (Grant No. 23034 [to MAM, AS]). This paper represents independent research part-supported by a scholarship supported from the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service (NHS) Foundation Trust and King's College London (to MAM, VK). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. We would like to thank the Centre for Neuroimaging Sciences' research staff for all their hard work and support throughout this research project. HVC's research is supported by the UK Medical Research Council and NIHR; she has consulted for Janssen on esketamine. MAM has received funding from Johnson & Johnson, Lundbeck, and Takeda and has acted as a consultant for Lundbeck and Takeda. MF is an employee of Janssen Research and Development. All other authors report no biomedical financial interests or potential conflicts of interest. ClinicalTrials.gov: Ketamine's Actions on Rumination Mechanisms as an Antidepressant (KARMA); <https://clinicaltrials.gov/ct2/show/NCT04656886>; NCT04656886